Average Upfront Payments in R&D-Stage Biotech Deals
Over the past several years, average upfront payments at R&D-stage deals have remained fairly constant. But deals from the first half of 1997 show a significant drop in both average upfront payments and total equity payments, suggesting drug companies are moving even farther than they have in the past away from discover-stage deals.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.